Active Biotech’s patent for laquinimod in eye disorders granted in the US

Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech’s US patent application 17/939,109 for laquinimod in eye disorders.

“We continue our dedicated work with the laquinimod patent portfolio to optimize protection for its use in sight-threatening eye disorders with high medical need,” said Active Biotech’s CEO Helén Tuvesson.

The patent is related to laquinimod in a method for treatment of eye diseases associated with excessive vascularization, e.g. wet age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy.

The patent number is US 12,208,091, and the patent will provide protection and market exclusivity in this field of use until 2040.

This follows a previous communication from Active Biotech on 13 November2024, that the USPTO had issued a Notice of Allowance.

Datum 2025-01-28, kl 08:30
Källa MFN
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.